|Articles|June 10, 2016
Oral Dose Development for Macromolecules
Author(s)Catalent Pharma Solutions
#wpbut {border: 3px solid #245998; border-radius:40px; border-color: #245998; padding: 15px 30px; font-size:15px !important;} #wpbut:hover {background: #15355a; color: #fff !important; transition: .5s;}
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
3
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
4
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
5
